(0.25%) 5 144.25 points
(0.20%) 38 519 points
(0.33%) 17 906 points
(-0.56%) $83.38
(1.98%) $1.961
(0.04%) $2 348.20
(0.32%) $27.62
(0.89%) $930.35
(-0.20%) $0.933
(-0.29%) $10.99
(-0.34%) $0.798
(1.14%) $92.92
@ $2.93
发出时间: 15 Feb 2024 @ 04:42
回报率: -42.56%
上一信号: Feb 15 - 03:49
上一信号:
回报率: -1.02 %
Live Chart Being Loaded With Signals
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients...
Stats | |
---|---|
今日成交量 | 1.25M |
平均成交量 | 1.41M |
市值 | 138.04M |
EPS | $-0.690 ( 2024-03-20 ) |
下一个收益日期 | ( $-0.350 ) 2024-05-14 |
Last Dividend | $0.0100 ( 2018-09-21 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.510 |
ATR14 | $0.00700 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-25 | Orbimed Advisors Llc | Buy | 1 841 100 | Common Stock |
2024-01-25 | Orbimed Advisors Llc | Buy | 1 041 700 | Common Stock |
2024-01-25 | Orbimed Advisors Llc | Buy | 242 200 | Common Stock |
2024-01-25 | Gordon Carl L | Buy | 1 841 100 | Common Stock |
2024-01-25 | Gordon Carl L | Buy | 1 041 700 | Common Stock |
INSIDER POWER |
---|
58.29 |
Last 100 transactions |
Buy: 13 014 935 | Sell: 4 163 691 |
音量 相关性
Aceto Corporation 相关性 - 货币/商品
Aceto Corporation 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-6.10M (0.00 %) |
EPS: | $-3.31 |
FY | 2023 |
营收: | $0 |
毛利润: | $-6.10M (0.00 %) |
EPS: | $-3.31 |
FY | 2022 |
营收: | $24.99M |
毛利润: | $19.98M (79.96 %) |
EPS: | $-1.630 |
FY | 2021 |
营收: | $9.73M |
毛利润: | $9.73M (100.00 %) |
EPS: | $-2.00 |
Financial Reports:
No articles found.
Aceto Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.100 | 2009-06-11 |
Last Dividend | $0.0100 | 2018-09-21 |
Next Dividend | $0 | N/A |
Payout Date | 2018-10-09 | |
Next Payout Date | N/A | |
# dividends | 32 | -- |
Total Paid Out | $2.12 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.82 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0.0850 | 0.75% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.682 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.689 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 8.41 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 8.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 8.28 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.101 | -1.500 | 8.32 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -6 335.00 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.18 | 2.00 | -0.726 | -1.452 | [0 - 30] |
freeCashFlowPerShareTTM | -2.28 | 2.00 | -1.141 | -2.28 | [0 - 20] |
debtEquityRatioTTM | 0.123 | -1.500 | 9.51 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.48 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.673 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.511 | 1.000 | -0.153 | 0 | [1 - 100] |
returnOnEquityTTM | -1.689 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.28 | 2.00 | -0.760 | -2.28 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.18 | 2.00 | -0.726 | -1.452 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0202 | 1.500 | -3.47 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -2.08 |
Aceto Corporation
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。